Bo Yoder S&P Update

The S&P 500 (ETF Proxy – AMEX:SPY) remains range-bound and biased to the downside.  While I would expect to see this latest bullish wave turn lower before new highs are seen, but the odds are poor at this time.  I will focus on other opportunities until this price action clears up and offers me a more advantaged entry.

SPY 1-17

 

Chevron Corp (NYSE:CVX) has performed well after “setting up” last week as a double bottom.  I would expect it to stall out near the resistance offered by the 50 period moving average near $110 per share. This offers a perfect opportunity to take some profits off the table and trail stops.  At this point I would expect that stops could be trailed to the $105 area, but the price action will dictate that exact level once resistance is tested.

CVX 1-17

Last week, I forecast that the SPYDR S&P Biotech ETF (NYSE:XBI) was likely to cycle back down to the $190 level before breaking out to a new high.  It reached a low of $188.96, and reversed with power.

With such an elegant entry, I would be aggressively taking profits to lock in gains as the market breaks out above the highs at $201.48, and would trail my stop to breakeven so as to take all risk off the table.

XBI 1-17

Be the first to comment on "Bo Yoder S&P Update"

Leave a comment

Your email address will not be published.


*


error

Enjoy this blog? Please spread the word :)